Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Table 2 Review of recent works on redo surgery for ductal adenocarcinoma metastatic recurrence

Ref.	Year	n	DFI (mo)	Site of recurrence	Surgery	Associated procedure	Morbidity	Mortality	SPR	OS
Kleeff et al[35]	2007	2	15.5	2 liver	1 left hemihepatectomy 1 right hemihepatectomy	/	NA	NA	23.5	NA
Arnaoutakis et al[40]	2011	9	34	9 lung	10 lung resection	/	1 AF	0	18.6	51
Thomas et al[34]	2012	14	52.4 (LR) 7.6 (LiR)	1 brain 6 liver 7 lung	4 RFA 10 resection	/	NA	0	NA	92.3 (LR); 32.5 (LiR)
Boone et al[39]	2013	12	34.35 (LR) 17 (LiR) 7.6 (Ovary)	6 liver 5 lung 1 ovary	4 liver resection 2 RFA 5 lung resection 1 hysterectomy + BSO	2 RFA	NA	0	20.1 (LR) 13.9 (LiR) 12.7 (ovary)	70.8 (LR) 29.8 (LiR) 20.3 (ovary)
Total		37	25.5 (me)	14 liver 21 lung 1 brain 1 ovary				0	18.6 (me)	41.75 (me)

DFI: Disease free interval; SPR: Survival post-reoperation; OS: Overall survival; LR: Lung recurrence; LiR: Liver recurrence; AF: Atrial fibrillation; RFA: Radiofrequency ablation; BSO: Bilateral salpingo-oophorectomy; NA: Not applicable; me: Median.